Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New and potential strategies for the treatment of PMM2-CDG

  • Gámez, Alejandra
  • Serrano, Mercedes
  • Gallego, Diana
  • Vilas, Alicia
  • Pérez, Belén
Background Mutations in the PMM2 gene cause phosphomannomutase 2 deficiency (PMM2; MIM# 212065), which manifests as a congenital disorder of glycosylation (PMM2-CDG). Mutant PMM2 leads to the reduced conversion of Man-6-P to Man-1-P, which results in low concentrations of guanosine 5′-diphospho-D-mannose, a nucleotide-activated sugar essential for the construction of protein oligosaccharide chains. To date the only therapeutic options are preventive and symptomatic. Scope of review This review covers the latest advances in the search for a treatment for PMM2-CDG. Major conclusions Treatments based on increasing Man-1-P levels have been proposed, along with the administration of different mannose derivates, employing enzyme inhibitors or repurposed drugs to increase the synthesis of GDP-Man. A single repurposed drug that might alleviate a severe neurological symptom associated with the disorder is now in clinical use. Proof of concept also exists regarding the use of pharmacological chaperones and/or proteostatic regulators to increase the concentration of hypomorphic PMM2 mutant proteins. General significance The ongoing challenges facing the discovery of drugs to treat this orphan disease are discussed., The authors are grateful to the Spanish families affected by PMM2-CDG who actively participated in this work. Financial support was provided by grant PI19/01155, PI17/00101, B2017/BMD-3721, the Fundación Isabel Gemio/Fundación La Caixa (LCF/PR/PR16/11110018), and the European Regional Development Fund. MS research is supported by the Generalitat de Catalunya (PERIS SLT008/18/00194., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Stroke-Like Episodes and Cerebellar Syndrome in Phosphomannomutase Deficiency (PMM2-CDG), Evidence for Hypoglycosylation-Driven Channelopathy

  • Izquierdo-Serra, Mercè|||0000-0002-3524-8052
  • Martínez-Monseny, Antonio F.
  • López López, Laura|||0000-0002-8653-6206
  • Carrillo-García, Julia
  • Edo Salvador, Ángel
  • Ortigoza-Escobar, Juan Darío
  • García Campos, Óscar
  • Cancho-Candela, Ramón|||0000-0001-6561-2209
  • Carrasco-Marina, M. Llanos
  • González Gutiérrez-Solana, Luis|||0000-0003-2890-4565
  • Cuadras, Daniel|||0000-0001-8780-1764
  • Muchart, Jordi
  • Montero, Raquel|||0000-0003-0609-5701
  • Artuch, R.|||0000-0002-3422-9685
  • Pérez-Cerdá, Celia
  • Pérez, Belén|||0000-0001-5801-1704
  • Pérez-Dueñas, Belén|||0000-0002-4979-2788
  • Macaya Ruiz, Alfons|||0000-0001-7998-4185
  • Fernández-Fernández, José Manuel|||0000-0003-2330-8449
  • Serrano, Mercedes|||0000-0002-2056-2428
Stroke-like episodes (SLE) occur in phosphomannomutase deficiency (PMM2-CDG), and may complicate the course of channelopathies related to Familial Hemiplegic Migraine (FHM) caused by mutations in CACNA1A (encoding Ca2.1 channel). The underlying pathomechanisms are unknown. We analyze clinical variables to detect risk factors for SLE in a series of 43 PMM2-CDG patients. We explore the hypothesis of abnormal Ca2.1 function due to aberrant N -glycosylation as a potential novel pathomechanism of SLE and ataxia in PMM2-CDG by using whole-cell patch-clamp, N -glycosylation blockade and mutagenesis. Nine SLE were identified. Neuroimages showed no signs of stroke. Comparison of characteristics between SLE positive versus negative patients' group showed no differences. Acute and chronic phenotypes of patients with PMM2-CDG or CACNA1A channelopathies show similarities. Hypoglycosylation of both Ca2.1 subunits (α and α) induced gain-of-function effects on channel gating that mirrored those reported for pathogenic CACNA1A mutations linked to FHM and ataxia. Unoccupied N -glycosylation site N283 at α contributes to a gain-of-function by lessening Ca2.1 inactivation. Hypoglycosylation of the αδ subunit also participates in the gain-of-function effect by promoting voltage-dependent opening of the Ca2.1 channel. Ca2.1 hypoglycosylation may cause ataxia and SLEs in PMM2-CDG patients. Aberrant Ca2.1 N -glycosylation as a novel pathomechanism in PMM2-CDG opens new therapeutic possibilities.